Immune cell score and therapeutic response to checkpoint inhibitors in patients with advanced lung cancer

Recruiting

• Conditions: C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00028745
• Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

Metastatic lung cancer, therapy with at least one checkpoint inhibitor as monotherapy or in combination with chemotherapy

Exclusion Criteria

Therapy in the context of other clinical studies in which the administered active substance is unclear

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is response to checkpoint inhibitors correlated with immune cell score. Response is assessed retrospectively based on the results of the respective staging examinations and the course of the disease.

Secondary Outcome Measures

Name	Time	Method
Other factors are considered as secondary endpoints to investigate whether they may be related to the immune cell score and the response to therapy. Other factors are the histological type, mutations (KRAS, MET, TP53), smoking status, possible radiation, etc.<br>All of the above factors are collected retrospectively from the patient files.